var data={"title":"Mercaptopurine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mercaptopurine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6537?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mercaptopurine-drug-information\" class=\"drug drug_general\">see &quot;Mercaptopurine: Drug information&quot;</a> and <a href=\"topic.htm?path=mercaptopurine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mercaptopurine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520198\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Purinethol [DSC];</li>\n      <li>Purixan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193228\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Purinethol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048478\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Purine</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048470\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mercaptopurine-drug-information\" class=\"drug drug_general\">see &quot;Mercaptopurine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients with minimal or no thiopurine S-methyltransferase (TPMT) activity are at increased risk for severe toxicity at conventional mercaptopurine doses and generally require dose reduction; consider TPMT gene polymorphism testing in patients who experience severe bone marrow suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Pediatric doses presented as mg/m<sup>2</sup> and mg/kg; use extra precaution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphoblastic leukemia (ALL):</b> Refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Children and Adolescents: Maintenance therapy: Oral: 1.5 to 2.5 mg/kg/dose once daily, combined with other agents. <b>Note:</b> Although the manufacturer provides suggested dosing (mg/kg), use has been replaced with BSA-directed dosing based on various protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available; multiple regimens reported.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Standard Risk (Bostrom 2003; Stork 2010): Children 1 to &lt;10 years: <i>Consolidation, Interim Maintenance I and Maintenance:</i> Oral: 75 mg/<b>m<sup>2</sup></b> once daily frequency and duration dependent on protocol phase (in combination with vincristine, steroid, methotrexate [oral and/or intrathecal]). Maintenance cycles are repeated for a total duration of 2 years (females) and 3 years (males) from the start of Interim Maintenance I. During Maintenance, oral methotrexate and mercaptopurine are adjusted to maintain a target absolute neutrophil count (ANC) goal (generally 1,000 to 2,000/mm<sup>3</sup>, varies based on protocol)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High risk (Larsen 2016): Children 1 to &lt;10 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Consolidation: </i>Oral: 60 mg/<b>m<sup>2</sup></b> once daily on days 1 to 14 and 29 to 42 of a 56-day cycle (in combination with cyclophosphamide, cytarabine, vincristine, pegaspargase, and intrathecal methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Interim Maintenance: </i>Oral: 25 mg/<b>m<sup>2</sup></b> once daily on days 1 to 56 (in combination with vincristine, high-dose methotrexate, and intrathecal methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i> Maintenance phase:</i> Oral: 75 mg/<b>m<sup>2</sup></b> once daily on days 1 to 84 of an 84-day cycle (in combination with vincristine, steroid, oral methotrexate, and intrathecal methotrexate). Maintenance cycles are repeated for a total duration of 2 years (females) and 3 years (males) from the start of Interim Maintenance I. During Maintenance, the oral methotrexate and mercaptopurine are titrated to a target absolute neutrophil count (ANC) goal (generally 1,000 to 2,000/mm<sup>3</sup>, varies based on protocol)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute promyelocytic leukemia (APL):</b> Limited data available; multiple regimens reported:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Combination with tretinoin: <i>Maintenance phase: </i>Children and Adolescents &le;14 years: Oral: 100 mg/<b>m<sup>2</sup></b>/day for 14 days of a 28-day cycle in combination with tretinoin. Cycles were repeated every 28 days for 2 years (Zhang 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Combination with tretinoin and methotrexate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ortega 2005: PETHEMA Group: <i>Maintenance phase: </i>Children and Adolescents &lt;17 years: Oral: 50 mg/<b>m<sup>2</sup></b>/day for 2 years in combination with methotrexate and tretinoin. Doses of mercaptopurine and methotrexate were decreased by 50% if the WBC count was &lt;3,500 cells/mm<sup>3</sup> and discontinued for WBC &lt;2,500/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Powell 2010: North American Leukemia Intergroup Study C9710: <i>Maintenance phase:</i> Adolescents &ge;15 years: Oral: 60 mg/<b>m<sup>2</sup></b>/day for 1 year; in combination with tretinoin and methotrexate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Autoimmune hepatitis:</b> Very limited data available: Children and Adolescents: Oral: 1.5 mg/kg/day in combination with prednisone; not considered first-line, typically used for patients who do not tolerate azathioprine (Manns 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammatory bowel disease (eg, Crohn disease, ulcerative colitis):</b> Limited data available: Children and Adolescents: Oral: 1 to 1.5 mg/kg/day (Markowitz 2000; Punati 2008; Sandhu 2010). Some data suggest that pediatric patients &le;6 years may require higher doses to achieve remission; a median dose of 1.68 mg/kg/day (maximum daily dose: 2.4 mg/kg/day) was reported to induce remission in 62% of patients vs 17% of those receiving lower doses (&lt;1.5 mg/kg/day study group; median dose: 1.18 mg/kg/day) (Grossman 2008; Sandborn 2001); maximum: 50 mg/day in the first week and increase to full dose when patients experience no adverse effects (Meijer 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:<b> Acute lymphoblastic leukemia (ALL):</b> Maintenance: Oral: 1.5 to 2.5 mg/kg/dose once daily (50 to 75 mg/m<sup>2</sup> once daily) continue based on blood counts</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment with concurrent allopurinol:</b> Children and Adolescents: Reduce mercaptopurine dosage; some protocols may require more aggressive reduction than others (Zerra 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in TPMT-deficiency:</b> Children and Adolescents: Dosing not established; substantial reductions are generally required only in homozygous deficiency; however, some experts also recommend dosage reduction with intermediate activity or heterozygous phenotype (Sandborn 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children and Adolescents: The manufacturer's labeling recommends starting with reduced doses in patients with renal impairment to avoid accumulation; however, no specific dosage adjustment is provided. The following adjustments have been used by some clinicians (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &le;50 mL/minute/1.73 m<sup>2</sup>: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults: The manufacturer&rsquo;s labeling recommends considering a reduced dose in patients with hepatic impairment; however, no specific dosage adjustment is provided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193204\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Purixan: 2000 mg/100 mL (100 mL) [contains aspartame, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Purinethol: 50 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193188\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25119580\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">For specialty or local pharmacy distribution and availability contact AnovoRx at http://www.purixan-us.com/find-purixan/ or call 888-470-0904.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048482\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer preferably on an empty stomach (Burton 1986; Kantarjian 2000); avoid concomitant milk products if possible (de Lemos 2007). Administer at the same time(s) each day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Acute lymphoblastic leukemia (ALL) treatment in children: Administration in the evening has demonstrated superior outcome; administration with food did not significantly affect outcome (Rivard 1985; Schmiegelow 1997)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If adherence is limited by administering on an empty stomach in the evening or by avoiding concomitant milk products, simplification of administration (eg, take with food/dairy without regard to time of day) should be considered. In adherent patients (taking mercaptopurine regularly), no association was seen between risk of ALL relapse and mercaptopurine ingestion habits; there was also no association noted with red cell thioguanine nucleotide (TGN) levels and administration with food, dairy, or time of day (Landier 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Suspension: Shake well for at least 30 seconds to ensure suspension is mixed thoroughly (suspension is viscous). Measure dose with an oral dosing syringe (a 1 mL and a 5 mL oral dosing syringe are supplied by the manufacturer) to assure proper dose is administered. If oral syringe is intended to be re-used, wash with warm soapy water and rinse well (hold syringe under water and move plunger several times to ensure inside of syringe is clean); allow to dry completely. Patients and caregivers should be trained on appropriate measuring and administration, handling, storage, disposal, cleanup of accidental spills, and proper cleaning of oral dosing syringe. Use within 8 weeks after opening.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132816\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193223\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Store in a dry place.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Do not store above 25&deg;C (77&deg;F). Store in a dry place. Use within 8 weeks after opening.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048481\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Maintenance treatment of acute lymphoblastic leukemia (ALL) in combination with other agents (eg, methotrexate) [FDA approved in pediatric patients (age not specified) and adults]; has also been used to treat inflammatory bowel disease, autoimmune hepatitis, and maintenance treatment in acute promyelocytic leukemia (APL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193278\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mercaptopurine may be confused with methotrexate</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Purinethol [DSC] may be confused with propylthiouracil </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mercaptopurine may be confused with mercaptamine [multiple international markets]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">To avoid potentially serious dosage errors, the terms &ldquo;6-mercaptopurine&rdquo; or &ldquo;6-MP&rdquo; should be avoided; use of these terms has been associated with sixfold overdosages.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azathioprine is metabolized to mercaptopurine; concurrent use of these commercially-available products has resulted in profound myelosuppression.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193275\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drug fever, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, hyperpigmentation, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperuricemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, cholestasis, diarrhea, mucositis, oral lesion, nausea (minimal), pancreatitis, sprue-like symptoms, stomach pain, ulcerative bowel lesion, vomiting (minimal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Oligospermia, renal toxicity, uricosuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic: Anemia, bone marrow depression (onset 7 to 10 days; nadir 14 days; recovery: 21 days), granulocytopenia, hemorrhage, hepatosplenic T-cell lymphomas, leukopenia, lymphocytopenia, metastases, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Ascites, hepatic encephalopathy, hepatic fibrosis, hepatic injury, hepatic necrosis, hepatomegaly, hepatotoxicity, hyperbilirubinemia, increased serum transaminases, intrahepatic cholestasis, jaundice, toxic hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immunosuppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hypoglycemia, portal hypertension, skin photosensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193212\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mercaptopurine or any component of the formulation; patients whose disease showed prior resistance to mercaptopurine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193192\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Dose-related leukopenia, thrombocytopenia, and anemia are common; however, may be indicative of disease progression. Hematologic toxicity may be delayed. Bone marrow may appear hypoplastic (could also appear normal). Monitor blood counts; dose may require adjusting for severe neutropenia or thrombocytopenia. Monitor for bleeding (due to thrombocytopenia) or infection (due to neutropenia). Profound severe or repeated hematologic toxicity may be indicative of thiopurine methyltransferase (TPMT) deficiency (see &ldquo;Thiopurine methyltransferase deficiency&rdquo; below).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity has been reported, including jaundice, ascites, hepatic necrosis (may be fatal), intrahepatic cholestasis, parenchymal cell necrosis, and/or hepatic encephalopathy; may be due to direct hepatic cell damage or hypersensitivity. While hepatotoxicity or hepatic injury may occur at any dose, dosages exceeding the recommended dose are associated with a higher incidence. Signs of jaundice generally appear early in treatment, after ~1 to 2 months (range: 1 week to 8 years) and may resolve following discontinuation; recurrence with rechallenge has been noted. Monitor liver function tests, including transaminases, alkaline phosphatase, and bilirubin weekly with treatment initiation, then monthly thereafter (monitor more frequently if used in combination with other hepatotoxic drugs or in patients with preexisting hepatic impairment). Consider a reduced dose in patients with baseline hepatic impairment; monitor closely for toxicity. Withhold treatment for clinical signs of jaundice (hepatomegaly, anorexia, tenderness), deterioration in liver function tests, toxic hepatitis, or biliary stasis until hepatotoxicity is ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Mercaptopurine is immunosuppressive; immune responses to infections may be impaired and the risk for infection is increased. Common signs of infection, such as fever and leukocytosis may not occur; lethargy and confusion may be more prominent signs of infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Macrophage activation syndrome: Macrophage activation syndrome (MAS), also known as hemophagocytic lymphohistiocytosis, is a life-threatening disorder which may develop in patients with autoimmune disorders (particularly inflammatory bowel disease); mercaptopurine use for the treatment of autoimmune conditions (off-label use) may cause increased susceptibility to MAS. Discontinue mercaptopurine if MAS develops or is suspected. Monitor; promptly treat infections such as Epstein-Barr virus (EBV) and cytomegalovirus (which are known triggers for MAS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Minimize sun exposure due to possible photosensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Immunosuppressive agents, including mercaptopurine, are associated with the development of lymphoproliferative disorders and other malignancies. In an analysis of T-cell lymphomas associated with TNF blockers (with or without thiopurines) for the treatment of rheumatoid arthritis, Crohn disease, ulcerative colitis, or ankylosing spondylitis (off-label uses for thiopurines), an increase in the incidence of T-cell lymphomas, most commonly mycosis fungoides/S&eacute;zary syndrome and hepatosplenic T-cell lymphoma (HSTCL) was reported (Deepak 2013). HSTCL is a rare white blood cell cancer that is usually fatal. Most HSTCL cases occurred in patients treated with a combination of TNF blockers and thiopurines, although cases of HSTCL also occurred in patients receiving azathioprine or mercaptopurine monotherapy. Skin cancers (melanoma and non-melanoma), Kaposi and non-Kaposi sarcomas, and uterine cervical cancer in situ have been reported in patients receiving immunosuppressive treatment (including mercaptopurine); risk of development may be related to the degree and duration of immunosuppression. Partial regression of lymphoproliferative disorders may occur upon therapy discontinuation. Regimens containing multiple immunosuppressants increase the risk of EBV-associated lymphoproliferative disorders; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Consider dosage modification in patients with renal impairment. Some renal adverse effects may be minimized with hydration and prophylactic antihyperuricemic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>NUDT15</i> genetic variation: A germline variant in nucleoside diphophate-linked moiety X-type motif 15 (<i>NUDT15</i>) is strongly correlated with mercaptopurine intolerance in children receiving treatment for acute lymphoblastic leukemia (ALL). A genome-wide association study was performed in two prospective clinical childhood ALL trials, and showed that patients homozygous for the TT genotype were extremely sensitive to mercaptopurine, and achieved an average dose intensity of only 8.3%. The <i>NUDT15</i> genetic variant is most common in East Asian and Hispanic patients. In patients homozygous for either TPMT or <i>NUDT15</i> (or heterozygous for both), mercaptopurine dose reductions of &ge;50% were required in 100% of patients (Yang 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thiopurine methyltransferase deficiency: Patients with homozygous genetic defect of TPMT are more sensitive to myelosuppressive effects; generally associated with rapid myelosuppression. Significant mercaptopurine dose reductions will be necessary (possibly with continued concomitant chemotherapy at normal doses). Patients who are heterozygous for TPMT defects will have intermediate activity; may have increased toxicity (primarily myelosuppression) although will generally tolerate normal mercaptopurine doses. Consider TPMT testing for severe toxicities/excessive myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Because azathioprine is metabolized to mercaptopurine, concomitant use with azathioprine may result in a significant increase in hematologic toxicity and profound myelosuppression; avoid concurrent use. Hematologic toxicity may be exacerbated by other medications which inhibit TPMT (eg, mesalamine, olsalazine, sulfasalazine) or by other myelosuppressive drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Cases of symptomatic hypoglycemia have been reported in children receiving mercaptopurine for the treatment of ALL; cases were reported in children less than 6 years of age or with a low body mass index.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Error-prone terms: To avoid potentially serious dosage errors, the terms &ldquo;6-mercaptopurine&rdquo; or &ldquo;6-MP&rdquo; should be avoided; use of these terms has been associated with six-fold overdosages.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Immune response to vaccines may be diminished. Live virus vaccines impose a risk for infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017159\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\"> The development of secondary hemophagocytic lymphohistiocytosis (HLH), a rare and frequently fatal activation of macrophages which causes phagocytosis of all bone marrow blood cell lines, is increased (100-fold) in pediatric patients diagnosed with inflammatory bowel disease; this risk is further increased with concomitant thiopurine (ie, azathioprine or mercaptopurine) therapy, Epstein-Barr virus, or other possible infections; if patient presents with fever (at least 5 days), cervical lymphadenopathy, and lymphopenia, discontinue immunosuppressive therapy and further diagnostic evaluation for HLH should be performed; diagnostic delay associated with increased mortality (Biank, 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299673\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193197\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12582&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May decrease the metabolism of Thiopurine Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase the serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides. Management: Reduce the mercaptopurine dose to one third to one quarter of the usual dose if used with allopurinol, and monitor closely for systemic toxicity. US labeling for mercaptopurine oral suspension (Purixan brand) recommends avoiding allopurinol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased.<b> Exceptions: </b>Lenalidomide; Pomalidomide; Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the myelosuppressive effect of Mercaptopurine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): May enhance the hepatotoxic effect of Mercaptopurine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May increase the serum concentration of Mercaptopurine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfamethoxazole: May enhance the myelosuppressive effect of Mercaptopurine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the myelosuppressive effect of Mercaptopurine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Mercaptopurine may enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live).  Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Mercaptopurine may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13842767\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Absorption is variable with food. Management: Preferably, take on an empty stomach at the same time each day 1 hour before or 2 hours after a meal. Maintain adequate hydration, unless instructed to restrict fluid intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193199\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13361082\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">May cause fetal harm if administered during pregnancy. Case reports of fetal loss have been noted with mercaptopurine administration during the first trimester; adverse effects have also been noted with second and third trimester use. Women of child bearing potential should avoid becoming pregnant during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048477\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For use in leukemia: CBC with differential (weekly initially, although clinical status may require increased frequency), bone marrow exam (to evaluate marrow status), liver function tests (weekly initially, then monthly; monitor more frequently if on concomitant hepatotoxic agents), renal function, urinalysis; consider TPMT genotyping to identify TPMT defect (if severe toxicity occurs) CBC with differential (weekly initially, although clinical status may require increased frequency), bone marrow exam (to evaluate marrow status), liver function tests (weekly initially, then monthly; monitor more frequently if on concomitant hepatotoxic agents), renal function, urinalysis; consider TPMT genotyping to identify TPMT defect (if severe toxicity occurs)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For use in inflammatory bowel disease: Monitor CBC with differential weekly for 1 month, then biweekly for 1 month, followed by monitoring every 1 to 2 months throughout the course of therapy. LFTs should be assessed every 3 months. Monitor for signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) (Sandhu 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193191\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mercaptopurine is a purine antagonist which inhibits DNA and RNA synthesis; acts as false metabolite and is incorporated into DNA and RNA, eventually inhibiting their synthesis; specific for the S phase of the cell cycle</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193211\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Variable and incomplete (~50% of a dose is absorbed); C<sub>max</sub> of suspension is 34% higher than the tablet</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: &gt; total body water; CNS penetration is poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~19%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and in GI mucosa; hepatically via xanthine oxidase and methylation via thiopurine methyltransferase to sulfate conjugates, 6-thiouric acid, and other inactive compounds; first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Tablets: Children: 21 minutes; Adults: 47 minutes; Suspension: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Within 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (46% as mercaptopurine and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193210\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 50 mg/mL oral suspension may be prepared in a vertical flow hood with tablets and a mixture of sterile water for injection (SWFI), simple syrup, and cherry syrup. Crush thirty 50 mg tablets in a mortar and reduce to a fine powder. Add ~5 mL SWFI and mix to a uniform paste; then add ~10 mL simple syrup; mix while continuing to add cherry syrup to make a final volume of 30 mL; transfer to a calibrated bottle. Label &quot;shake well&quot; and &quot;caution chemotherapy&quot;. Stable for 35 days at room temperature.</p>\n    <div class=\"reference\">Aliabadi HM, Romanick M, Desai, S, et al, &ldquo;Effect of Buffer and Antioxidant on Stability of a Mercaptopurine Suspension,&rdquo; <i>Am J Health Syst Pharm</i> 2008, 65(5):441-7. <span class=\"pubmed-id\">18281736</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193214\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Purixan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 mg/100 mL (100 mL): $1,362.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mercaptopurine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (25): $102.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193216\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>6-MP (LK);</li>\n      <li>Capmerin (PH);</li>\n      <li>Empurine (PH, TH);</li>\n      <li>Leukin (BD);</li>\n      <li>Mercaptopurina (ES);</li>\n      <li>Merkaptopurin (TW);</li>\n      <li>Merpurin (PH);</li>\n      <li>Puri-Nethol (AE, AT, BE, BF, BG, BH, BJ, CH, CI, CY, CZ, DE, EE, EG, ET, FI, GB, GH, GM, GN, HK, HR, ID, IE, IL, IN, IQ, IR, IS, JO, KE, KR, KW, LB, LR, LT, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NO, NZ, OM, QA, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TR, TZ, UG, UY, VN, YE, ZA, ZM, ZW);</li>\n      <li>Purinethjol (PA);</li>\n      <li>Purinethol (AR, CL, CR, DO, FR, GR, GT, HN, IT, MX, NI, NL, PH, PL, RU, SV);</li>\n      <li>PuriNethol (AU);</li>\n      <li>Purinetone (PK, SG);</li>\n      <li>Varimer (PE, PY);</li>\n      <li>Xaluprine (AT, DK, GB, HR, HU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, 173.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biank VF, Sheth MK, Talano J, et al, &quot;Association of Crohn's disease, Thiopurines, and Primary Epstein-Barr Virus Infection With Hemophagocytic Lymphohistiocytosis,&quot; <i>J Pediatr</i>, 2011, 159(5):808-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/21722918/pubmed\" target=\"_blank\" id=\"21722918\">21722918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children&rsquo;s Cancer Group. <i>Blood.</i> 2003;101(10):3809-3817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/12531809/pubmed\" target=\"_blank\" id=\"12531809\">12531809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burton NK, Barnett MJ, Aherne GW, et al. The effect of food on the oral administration of 6-mercaptopurine. <i>Cancer Chemother Pharmacol</i>. 2986;18(1):90-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/3757164/pubmed\" target=\"_blank\" id=\"3757164\">3757164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deepak P, Sifuentes H, Sherid M, et al, &ldquo;T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-&alpha;) Inhibitors: Results of the REFURBISH Study,&rdquo; <i>Am J Gastroenterol</i>, 2013, 108(1):99-105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/23032984/pubmed\" target=\"_blank\" id=\"23032984\">23032984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ, Gearry RB, Roberts RL, et al, &ldquo;Exposure to Thiopurine Drugs Through Breast Milk is Low Based on Metabolite Concentrations in Mother-Infant Pairs,&rdquo; <i>Br J Clin Pharmacol</i>, 2006, 62(4):453-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/16995866/pubmed\" target=\"_blank\" id=\"16995866\">16995866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gremse DA and Crissinger KD, &ldquo;Ulcerative Colitis in Children: Medical Management,&rdquo; <i>Paediatr Drugs</i>, 2002, 4(12):807-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/12431133/pubmed\" target=\"_blank\" id=\"12431133\">12431133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grossman AB, Noble AJ, Mamula P, et al, &quot;Increased Dosing Requirements for 6-Mercaptopurine and Azathioprine in Inflammatory Bowel Disease Patients Six Years and Younger,&quot; <i>Inflamm Bowel Dis</i>, 2008, 14(6):750-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/18266236/pubmed\" target=\"_blank\" id=\"18266236\">18266236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, O'Brien S, Smith TL, et al, &ldquo;Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2000, 18(3): 547-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/10653870 /pubmed\" target=\"_blank\" id=\"10653870 \">10653870 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landier W, Hageman L, Chen Y, et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children&rsquo;s Oncology Group study AALL03N1. <i>J Clin Oncol.</i> 2017;35(15):1730-1736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/28339328/pubmed\" target=\"_blank\" id=\"28339328\">28339328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children&rsquo;s Oncology Group Study AALL0232. <i>J Clin Oncol.</i> 2016;34(20):2380-2388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/27114587/pubmed\" target=\"_blank\" id=\"27114587\">27114587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo; <i>Blood</i>, 1995, 85(8):2025-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/7718875 /pubmed\" target=\"_blank\" id=\"7718875 \">7718875 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Linker CA, et al, &quot;A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111,&quot; <i>Blood</i>, 1998, 92(5):1556-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/9716583/pubmed\" target=\"_blank\" id=\"9716583\">9716583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manns MP, Czaja AJ, Gorham JD, et al, &ldquo;Diagnosis and Management of Autoimmune Hepatitis,&rdquo; <i>Hepatology</i>, 2010, 51(6):2193-213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/20513004/pubmed\" target=\"_blank\" id=\"20513004\">20513004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Markowitz J, Grancher K, Kohn N, et al, &ldquo;A Multicenter Trial of 6-Mercaptopurine and Prednisone in Children With Newly Diagnosed Crohn's Disease,&rdquo; <i>Gastroenterology</i>, 2000, 119(4):895-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/11040176/pubmed\" target=\"_blank\" id=\"11040176\">11040176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: a systematic review. <i>World J Gastroenterol</i>. 2016;22(40):9012-9021.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/27833392/pubmed\" target=\"_blank\" id=\"27833392\">27833392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mosesso P and Palitti F, &quot;The Genetic Toxicology of 6-Mercaptopurine,&quot; <i>Mutat Res</i>, 1993, 296(3):279-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/7680107/pubmed\" target=\"_blank\" id=\"7680107\">7680107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega JJ, Madero L, Mart&iacute;n G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. <i>J Clin Oncol</i>. 2005;23(30):7632-7640.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/16234524/pubmed\" target=\"_blank\" id=\"16234524\">16234524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo; <i>Eur J Gastroenterol Hepatol</i>, 2011, 23(12):1150-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/21941193/pubmed\" target=\"_blank\" id=\"21941193\">21941193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo; <i>Blood</i>, 2010, 116(19):3751-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/20705755/pubmed\" target=\"_blank\" id=\"20705755\">20705755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Punati J, Markowitz J, Lerer T, et al, &quot;Effect of Early Immunomodulator Use in Moderate to Severe Pediatric Crohn Disease,&quot; <i>Inflamm Bowel Dis</i>, 2008, 14(7):949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/18306311/pubmed\" target=\"_blank\" id=\"18306311\">18306311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rivard GE, Infante-Rivard C, Hoyoux C, Champagne J. Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening. <i>Lancet</i>. 1985;2(8467):1264-1266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/2866334/pubmed\" target=\"_blank\" id=\"2866334\">2866334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. <i>Gut</i>. 2001;48(5):591-592.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/11302950/pubmed\" target=\"_blank\" id=\"11302950\">11302950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ, &ldquo;A Review of Immune Modifier Therapy for Inflammatory Bowel Disease: Azathioprine, 6-mercaptopurine, Cyclosporine, and Methotrexate,&rdquo; <i>Am J Gastroenterol</i>, 1996, 91(3):423-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/8633486/pubmed\" target=\"_blank\" id=\"8633486\">8633486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Fell JME, Beattie RM, et al, &ldquo;Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom.&rdquo; <i>JPGN</i>, 2010, 50:1-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmiegelow K, Glomstein A, Kristinsson J, et al, &ldquo;Impact of Morning versus Evening Schedule for Oral Methotrexate and 6-Mercaptopurine on Relapse Risk for Children With Acute Lymphoblastic Leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO),&rdquo; <i>J Pediatr Hematol Oncol</i>, 1997, 19(2):102-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/9149738/pubmed\" target=\"_blank\" id=\"9149738\">9149738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. <i>Blood</i>. 2000;95(11):3310-3322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/10828010/pubmed\" target=\"_blank\" id=\"10828010\">10828010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i>. 2008;111(5):2548-2555.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/18039957/pubmed\" target=\"_blank\" id=\"18039957\">18039957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stock W, La M, Sanford B, et al, &ldquo;What Determines the Outcomes for Adolescents and Young Adults With Acute Lymphoblastic Leukemia Treated on Cooperative Group Protocols? A Comparison of Children's Cancer Group and Cancer and Leukemia Group B Studies,&rdquo; <i>Blood</i>, 2008, 112(5):1646-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/18502832/pubmed\" target=\"_blank\" id=\"18502832\">18502832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stork LC, Matloub Y, Broxson E, et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. <i>Blood</i>. 2010;115(14):2740-2748.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/20124218/pubmed\" target=\"_blank\" id=\"20124218\">20124218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winter SS, Dunsmore KP, Devidas M, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatr Blood Cancer</i>. 2015;62(7):1176-1183.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/25755211/pubmed\" target=\"_blank\" id=\"25755211\">25755211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2015;33(11):1235-1242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/25624441/pubmed\" target=\"_blank\" id=\"25624441\">25624441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zerra P, Bergsagel J, Keller FG, Lew G, Pauly M. Maintenance treatment with low-dose mercaptopurine in combination with allopurinol in children with acute lymphoblastic leukemia and mercaptopurine-induced pancreatitis. <i>Pediatr Blood Cancer</i>. 2016;63(4):712-715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/26878433/pubmed\" target=\"_blank\" id=\"26878433\">26878433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang L, Zhu X, Chen X, Chen Y, Zou Y. The role of standard-dose cytarabine in children with acute promyelocytic leukemia: a single-center experience. <i>J Pediatr Hematol Oncol</i>. 2011;33(2):e46-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mercaptopurine-pediatric-drug-information/abstract-text/21127433/pubmed\" target=\"_blank\" id=\"21127433\">21127433</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12582 Version 146.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520198\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193228\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048478\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048470\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193204\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F193188\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F25119580\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048482\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132816\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F193223\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048481\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F193278\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193275\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193212\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193192\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017159\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299673\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193197\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13842767\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193199\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13361082\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048477\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193191\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F193211\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F193210\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F193214\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193216\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12582|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mercaptopurine-drug-information\" class=\"drug drug_general\">Mercaptopurine: Drug information</a></li><li><a href=\"topic.htm?path=mercaptopurine-patient-drug-information\" class=\"drug drug_patient\">Mercaptopurine: Patient drug information</a></li></ul></div></div>","javascript":null}